Mandy van Gulijk

Mandy van Gulijk

Auto-generated profile, based on publicly available information

Mandy van Gulijk

Department of Pulmonary Medicine, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Science Immunology
Verified
Journal Article
Closed access
MGMandy van Gulijk
Mandy van Gulijk
AKAnneloes van Krimpen
Anneloes van Krimpen
SSSjoerd T.T. Schetters
Sjoerd T.T. Schetters
MEMike Eterman
Mike Eterman
MEMarit J. van Elsas
Marit J. van Elsas
THThorbald van Hall
Thorbald van Hall
Despite the clinical success of immune checkpoint blockade (ICB), in certain cancer types, most patients with cancer do not respond well. Furthermore, in patients for whom ICB is initially successful, this is often short-lived because of the development of resistance to ICB. The mechanisms underlying primary or secondary ICB resistance are incompletely understood. Here, we identified preferential activation and enhanced suppressive capacity of regulatory T cells (T reg cells) in αPD-L1 therapy–resistant solid tumor–bearing mice. T reg cell depletion reversed resistance to αPD-L1 with concomitant expansion of effector T cells. Moreover, we found that tumor-infiltrating T reg cells in human patients with skin cancer, and in patients with non–small cell lung cancer, up-regulated a suppressive transcriptional gene program after ICB treatment, which correlated with lack of treatment response. αPD-1/PD-L1–induced PD-1 + T reg cell activation was also seen in peripheral blood of patients with lung cancer and mesothelioma, especially in nonresponders. Together, these data reveal that treatment with αPD-1 and αPD-L1 unleashes the immunosuppressive role of T reg cells, resulting in therapy resistance, suggesting that T reg cell targeting is an important adjunct strategy to enhance therapeutic efficacy.

23 June 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
FDFloris Dammeijer
Floris Dammeijer
MGMandy van Gulijk
Mandy van Gulijk
LKLarissa Klaase
Larissa Klaase
MNMenno van Nimwegen
Menno van Nimwegen
RBRachid Bouzid
Rachid Bouzid
JAJoachim G. Aerts
Joachim G. Aerts
Terminal T-cell exhaustion poses a significant barrier to effective anticancer immunotherapy efficacy, with current drugs aimed at reversing exhaustion being limited. Recent investigations into the molecular drivers of T-cell exhaustion have led to the identification of chronic IL2 receptor (IL2R)–STAT5 pathway signaling in mediating T-cell exhaustion. We targeted the key downstream IL2R-intermediate JAK 3 using a clinically relevant highly specific JAK3-inhibitor (JAK3i; PF-06651600) that potently inhibited STAT5-phosphorylation in vitro. Whereas pulsed high-dose JAK3i administration inhibited antitumor T-cell effector function, low-dose chronic JAK3i significantly improved T-cell responses and decreased tumor load in mouse models of solid cancer. Low-dose JAK3i combined with cellular and peptide vaccine strategies further decreased tumor load compared with both monotherapies alone. Collectively, these results identify JAK3 as a novel and promising target for combination immunotherapy.

3 October 2022 in International Journal of Cancer
Verified
Journal Article
Open access
MGMandy van Gulijk
Mandy van Gulijk
BBBob Belderbos
Bob Belderbos
DDDaphne Dumoulin
Daphne Dumoulin
RCRobin Cornelissen
Robin Cornelissen
KBKoen Bezemer
Koen Bezemer
JAJoachim G. Aerts
Joachim G. Aerts
Immunotherapy with anti‐PD1/PD‐L1 is effective in only a subgroup of patients with malignant pleural mesothelioma (MPM). We investigated the efficacy of a combination of anti‐PD1/PD‐L1 and dendritic cell (DC) therapy to optimally induce effective anti‐tumor immunity in MPM in both humans and mice. Data of nine MPM patients treated with DC therapy and sequential anti‐PD1 treatment were collected and analyzed for progression‐free survival (PFS) and overall survival (OS). Survival and T‐cell responses were monitored in AC29 mesothelioma‐bearing mice treated concurrently with the combination therapy; additionally, the role of the tumor‐draining lymph node (TDLN) was investigated. The combination therapy resulted in a median OS and PFS of 17.7 and 8.0 months, respectively. Grade 3 to 4 treatment‐related adverse events had not been reported. Survival of the mesothelioma‐bearing mice treated with the combination therapy was longer than that of untreated mice, and coincided with improved T‐cell activation in peripheral blood and less T‐cell exhaustion in end stage tumors. Comparable results were obtained when solely the TDLN was targeted. We concluded that this combination therapy is safe and shows promising OS and PFS. The murine data support that PD‐L1 treatment may reinvigorate the T‐cell responses induced by DC therapy, which may primarily be the result of TDLN targeting.


3 April 2023
Verified
Other
Open access
FDFloris Dammeijer
Floris Dammeijer
MGMandy van Gulijk
Mandy van Gulijk
LKLarissa Klaase
Larissa Klaase
MNMenno van Nimwegen
Menno van Nimwegen
RBRachid Bouzid
Rachid Bouzid
JAJoachim G. Aerts
Joachim G. Aerts
Terminal T-cell exhaustion poses a significant barrier to effective anticancer immunotherapy efficacy, with current drugs aimed at reversing exhaustion being limited. Recent investigations into the molecular drivers of T-cell exhaustion have led to the identification of chronic IL2 receptor (IL2R)–STAT5 pathway signaling in mediating T-cell exhaustion. We targeted the key downstream IL2R-intermediate JAK 3 using a clinically relevant highly specific JAK3-inhibitor (JAK3i; PF-06651600) that potently inhibited STAT5-phosphorylation in vitro. Whereas pulsed high-dose JAK3i administration inhibited antitumor T-cell effector function, low-dose chronic JAK3i significantly improved T-cell responses and decreased tumor load in mouse models of solid cancer. Low-dose JAK3i combined with cellular and peptide vaccine strategies further decreased tumor load compared with both monotherapies alone. Collectively, these results identify JAK3 as a novel and promising target for combination immunotherapy.

3 April 2023
Verified
Other
Open access
FDFloris Dammeijer
Floris Dammeijer
MGMandy van Gulijk
Mandy van Gulijk
LKLarissa Klaase
Larissa Klaase
MNMenno van Nimwegen
Menno van Nimwegen
RBRachid Bouzid
Rachid Bouzid
JAJoachim G. Aerts
Joachim G. Aerts
Supplementary Figure from Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy